dalteparin has been researched along with Non-ST Elevated Myocardial Infarction in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Non-ST Elevated Myocardial Infarction: A myocardial infarction that does not produce elevations in the ST segments of the ELECTROCARDIOGRAM. ST segment elevation of the ECG is often used in determining the treatment protocol (see also ST Elevation Myocardial Infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 8.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "There are limited data on bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme)." | 7.96 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triag ( Bansilal, S; Ben-Yehuda, O; Brener, SJ; Chen, S; Dangas, GD; Feite, F; Huang, X; Kirtane, AJ; Mehran, R; Redfors, B; Souza, CF; Stone, GW; Zhang, Y, 2020) |
| "In patients with NSTE-ACS undergoing an early invasive strategy, treatment with bivalirudin alone significantly reduced major bleeding and improved net clinical outcomes during the upstream medical management phase with comparable rates of MACE." | 5.22 | Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial. ( Bernstein, D; Bertrand, ME; Cequier, AR; Deliargyris, EN; Desmet, W; Droppa, M; Gawaz, M; Geisler, T; Hoekstra, JW; Lincoff, AM; Mehran, R; Rasmussen, LH; Steinhubl, SR; Stone, GW, 2016) |
| "Enoxaparin and Fondaparinux are potential anticoagulants which are used peri-operatively in the management of patients with Acute Coronary Syndrome (ACS)." | 4.95 | Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. ( Bundhun, PK; Shaik, M; Yuan, J, 2017) |
| "There are limited data on bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme)." | 3.96 | Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triag ( Bansilal, S; Ben-Yehuda, O; Brener, SJ; Chen, S; Dangas, GD; Feite, F; Huang, X; Kirtane, AJ; Mehran, R; Redfors, B; Souza, CF; Stone, GW; Zhang, Y, 2020) |
| "Risk of bleeding was assessed with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) scale, and risk of major bleeding in patients with NSTEMI was additionally assessed with the CRUSADE scale." | 1.72 | Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. ( Boytsov, SA; Erlikh, AD; Gulyan, RG; Pevsner, DV; Shakhnovich, RM; Tereschenko, SN, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boytsov, SA | 3 |
| Shakhnovich, RM | 3 |
| Tereschenko, SN | 3 |
| Erlikh, AD | 3 |
| Pevsner, DV | 3 |
| Gulyan, RG | 3 |
| Huang, X | 1 |
| Chen, S | 1 |
| Redfors, B | 1 |
| Zhang, Y | 1 |
| Souza, CF | 1 |
| Mehran, R | 2 |
| Bansilal, S | 1 |
| Kirtane, AJ | 1 |
| Brener, SJ | 1 |
| Feite, F | 1 |
| Dangas, GD | 1 |
| Ben-Yehuda, O | 1 |
| Stone, GW | 2 |
| Bundhun, PK | 1 |
| Shaik, M | 1 |
| Yuan, J | 1 |
| Geisler, T | 1 |
| Droppa, M | 1 |
| Gawaz, M | 1 |
| Steinhubl, SR | 1 |
| Bertrand, ME | 1 |
| Lincoff, AM | 1 |
| Cequier, AR | 1 |
| Desmet, W | 1 |
| Rasmussen, LH | 1 |
| Hoekstra, JW | 1 |
| Bernstein, D | 1 |
| Deliargyris, EN | 1 |
1 review available for dalteparin and Non-ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Chi-Square Distribution; Enoxaparin; Female; Fondapar | 2017 |
1 trial available for dalteparin and Non-ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Coronary Artery Bypass; Drug Therapy, | 2016 |
2 other studies available for dalteparin and Non-ST Elevated Myocardial Infarction